Want to see INGN full AI Analyst Report?
INGN Stock Chart & Stats
$5.54
-$0.17(-2.69%)
At close: 4:00 PM EDT
$5.54
-$0.17(-2.69%)
Day’s Range― - ―
52-Week Range$5.34 - $9.13
Previous CloseN/A
Volume233.40K
Average Volume (3M)387.79K
Market Cap
$145.96M
Enterprise Value$83.39
Total Cash (Recent Filing)$105.54M
Total Debt (Recent Filing)$15.79M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding26,538,338
10 Day Avg. Volume310,281
30 Day Avg. Volume387,791
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)0.95
Price to Sales (P/S)0.52
P/FCF Ratio-8.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside134.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$369.13M
Bulls Say, Bears Say
Bulls Say
International GrowthSustained double-digit international growth indicates expanding geographic reach and demand beyond the pressured U.S. channels. Repeated growth across ten quarters can diversify revenue and provide a durable foundation for future scale.
New Product AdoptionEarly adoption of Voxi and Aurora demonstrates product pipeline traction and supports portfolio diversification. Continued launches can strengthen competitive positioning, expand addressable demand, and improve growth beyond legacy device offerings.
Low Leverage And LiquidityA debt-free balance sheet and substantial liquidity provide flexibility to fund product development, commercial expansion, and operational improvements. This reduces refinancing risk and gives management time to execute its broader respiratory-care strategy.
Bears Say
Persistent Losses And Cash BurnRevenue and margins have improved, but Inogen has not yet converted that progress into sustainable GAAP earnings or consistent free cash flow. Continued losses could erode equity and liquidity, increasing reliance on operational turnaround execution.
U.S. Channel PressureThe shift away from direct-to-consumer sales and traditional rentals can weigh on revenue mix and customer acquisition economics. B2B growth may not fully offset these channels, creating a durable constraint on U.S. growth and profitability.
Reimbursement And Regulatory UncertaintyUncertain reimbursement and regulatory timelines can delay adoption of new respiratory products and limit market access. Additional clinical evidence and approvals may require further investment before Simeox and selected devices contribute materially.
Inogen News
INGN FAQ
What was Inogen’s price range in the past 12 months?
Inogen lowest stock price was $5.34 and its highest was $9.13 in the past 12 months.
What is Inogen’s market cap?
Inogen’s market cap is $145.96M.
When is Inogen’s upcoming earnings report date?
Inogen’s upcoming earnings report date is Nov 11, 2026 which is in 76 days.
How were Inogen’s earnings last quarter?
Inogen released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.153 by $0.013.
Is Inogen overvalued?
According to Wall Street analysts Inogen’s price is currently Undervalued.
Does Inogen pay dividends?
Inogen does not currently pay dividends.
What is Inogen’s EPS estimate?
Inogen’s EPS estimate is -0.13.
How many shares outstanding does Inogen have?
Inogen has 26,538,338 shares outstanding.
What happened to Inogen’s price movement after its last earnings report?
Inogen reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.153. Following the earnings report the stock price went down -6.78%.
Which hedge fund is a major shareholder of Inogen?
Currently, no hedge funds are holding shares in INGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inogen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.00 (134.66% Upside)
$13.00 (134.66% Upside)
Blogger Sentiment
Bullish
INGN Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 9.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.48%
Trailing 12-Months
Company Description
Inogen
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
INGN Company Deck
INGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear commercial and product progress — notably strong international revenue growth (+15% YoY), continued POC unit expansion (>12% YoY), early traction for new products (Voxi shipments >5,000; Aurora account count doubled), margin improvement (adjusted gross margin +65 bps) and a raised adjusted EBITDA outlook. Offsetting these positives are ongoing headwinds in the U.S. DTC channel (U.S. sales -2% YoY), a 12% decline in rental revenue, a downward revision to full-year revenue guidance (midpoint reduction of ~ $11.5M), and continued dependency on distributor purchase timing and reimbursement/regulatory milestones. Overall the company shows momentum in strategic growth areas and improved unit economics, but macro and channel mix pressures keep near-term top-line growth constrained.View all INGN earnings summariesINGN Stock 12 Month Forecast
Average Price Target
$13.00
▲(134.66% Upside)
Technical Analysis
Ownership Overview
3.65% Insiders
16.96% Mutual Funds
16.37% Other Institutional Investors
52.79% Public Companies and
Individual Investors